×
NAYA Biosciences Inventory 2010-2024 | NAYA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
NAYA Biosciences inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
View More
NAYA Biosciences Inventory 2010-2024 | NAYA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
NAYA Biosciences inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$169.8B
Vertex Pharmaceuticals (VRTX)
$121.4B
Gilead Sciences (GILD)
$109.7B
Bristol Myers Squibb (BMY)
$106.4B
Regeneron Pharmaceuticals (REGN)
$102.2B
CSL (CSLLY)
$92.8B
GSK (GSK)
$79.1B
Alnylam Pharmaceuticals (ALNY)
$36.5B
Argenex SE (ARGX)
$33.1B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$26.7B
Illumina (ILMN)
$23.3B
Moderna (MRNA)
$21.2B
BeiGene (BGNE)
$21.1B
Genmab (GMAB)
$15.3B
Incyte (INCY)
$14.2B
BioMarin Pharmaceutical (BMRN)
$13.3B
Exact Sciences (EXAS)
$12.9B
Sarepta Therapeutics (SRPT)
$12.4B
Insmed (INSM)
$12.2B
Vaxcyte (PCVX)
$11.8B
Bio-Techne Corp (TECH)
$11.2B
QIAGEN (QGEN)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Revolution Medicines (RVMD)
$8.4B
Legend Biotech (LEGN)
$8.3B
Exelixis (EXEL)
$8.2B
Viking Therapeutics (VKTX)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B